Navigation Links
In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function
Date:11/7/2010

NEW YORK, Nov. 7, 2010 /PRNewswire-FirstCall/ -- Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates and mean change in HAQ-DI, respectively, versus placebo at three months. For a third primary endpoint, the rate of DAS28-4(ESR) <2.6, a measure of disease remission, treatment with tasocitinib resulted in a numerically greater, but not statistically significant difference from placebo at three months.

(Logo: http://photos.prnewswire.com/prnh/20100416/PFIZERLOGO)

(Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO)

In ORAL Solo, a similar frequency of adverse events was seen across all treatment groups. Serious adverse events were reported in 4.1 percent of patients. Additionally, decreases in neutrophil count and hemoglobin and an increase in cholesterol occurred by month three. These changes tended to stabilize thereafter. No new safety signals were detected.

"We are encouraged by the statistically significant and clinically meaningful improvements we observed in a proportion of patients treated with tasocitinib monotherapy in ORAL Solo," said Roy Fleischmann, MD, Clinical Professor in the Department of Internal Medicine at the University of Texas Southwestern Medical Center in Dallas.  "Further research into additional treatment options for patients with moderately to severely active RA is important, and we look forward to seeing the results of the additional Phase 3 ORAL trials of tasocitinib."

ORAL Sequel (1024), an open label, follow-up Phase 2/3 study,
'/>"/>

SOURCE Pfizer Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ThermoGenesis Reports 35 Percent Increase in First Quarter 2011 Revenues, Adds Strategic Advisor and Inks China Distribution Deal With Nanshan Memorial Medical Institute
2. Genoptix Reports Operating Results for the Third Quarter and First Nine Months of 2010
3. Unilife Corporation Schedules Fiscal 2011 First Quarter Conference Call For Monday, November 15, 2010
4. Regado Biosciences, Inc. Presents the First-In-Human Clinical Experience with REG2 at the American College of Chest Physicians (ACCP) Coagulation and Heart Disease Sessions in Vancouver, BC, Canada on November 2, 2010
5. GREENGUARDs First Exhibit at HEALTHCARE DESIGN.10 to Help Architects and Designers Specify Healthier Products More Easily and Efficiently
6. CareFusion Reports First Quarter Fiscal 2011 Results; Reaffirms Fiscal 2011 Financial Guidance
7. Endologix Announces First Clinical Implant of Ventana™ Stent Graft
8. NeurogesX Doses First Patient in Phase 2 Clinical Study of NGX-1998 Liquid Capsaicin Formulation
9. PAREXEL Reports First Quarter Fiscal Year 2011 Financial Results
10. Octapharma Clinical Trial Begins in the U.S. and Germany Treating Hemophilia A Patients with First Recombinant Factor VIII Derived from a Human Cell-Line
11. VIDEO from thenewsmarket.com and Novartis: Novartis drug Afinitor® Approved by FDA as First Medication for Children and Adults With a Benign Brain Tumor Associated With Tuberous Sclerosis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)...  EndoChoice Holdings, Inc. (NYSE:  GI) announced today that ... on Thursday, August 6, 2015 before the market open. ... on Thursday, August 6, 2015 at 9:00 a.m. ET ... 807-9684 for domestic callers and (412) 317-5415 for international ... be available on the investor relations section of the ...
(Date:7/6/2015)... 2015  OrthoSpace Ltd. ("OrthoSpace" or "Company") announced ... in its US Investigational Device Exemption (IDE) pivotal ... single blinded control study that compares the Company,s ... partial repair for the treatment of full thickness ... commercially available outside of the United ...
(Date:7/6/2015)... - The Canadian Pharmacists Association (CPhA) urges the federal government ... all Canadians have the opportunity to protect themselves against ... The lack of access to HPV vaccination programs for ... needlessly putting the health of Canadians at risk. ... pose a significant threat to the health of Canadians," ...
Breaking Medicine Technology:EndoChoice to Report Second Quarter 2015 Financial Results on August 6, 2015 2OrthoSpace Enrolls First Patients in US IDE Study 2CPhA Calls for HPV Strategy for Young Men to Save Lives 2
... MiMedx Group, Inc.  (OTCBB: MDXG), an integrated developer, manufacturer ... processed from human amniotic membrane, announced today its results ... 30, 2011. The Company recorded record revenue ... over second quarter of 2011 revenue of $1,929,000 and ...
... Oct. 26, 2011 Reportlinker.com ... research report is available in ... Early Stage Drug Safety Strategies ... towards achieving clinical success ...
Cached Medicine Technology:MiMedx Group Announces Third Quarter 2011 Results 2MiMedx Group Announces Third Quarter 2011 Results 3MiMedx Group Announces Third Quarter 2011 Results 4MiMedx Group Announces Third Quarter 2011 Results 5MiMedx Group Announces Third Quarter 2011 Results 6MiMedx Group Announces Third Quarter 2011 Results 7MiMedx Group Announces Third Quarter 2011 Results 8MiMedx Group Announces Third Quarter 2011 Results 9MiMedx Group Announces Third Quarter 2011 Results 10Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 2Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 3Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 4Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 5Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 6Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 7Early Stage Drug Safety Strategies and Risk Management: Maximizing opportunities towards achieving clinical success 8
(Date:7/7/2015)... ... , ... Dr. Poneh Ghasri , cosmetic dentist in Los Angeles, is ... one of the fastest, easiest ways to brighten a smile. Stained teeth can add ... confidence. With the right teeth whitening treatment, patients can restore a more youthful appearance ...
(Date:7/7/2015)... ... 2015 , ... Office Practicum announced today that it has ... effective July 6th, 2015. Ellen joins Office Practicum with more than 27 years ... chemical company to early and growth-stage technology companies. , Purdy joins Office ...
(Date:7/7/2015)... ... July 07, 2015 , ... ISI ... announced the release of Service Pack 5600 for its Call Accounting and ... enhancements to the already robust capabilities of the reporting platform, including updates ...
(Date:7/7/2015)... (PRWEB) , ... July 07, 2015 , ... Connexion Point is holding an onsite job ... be held at 1769 Paragon Place, Suite 100, this upcoming Wednesday, July 8, and Thursday, ... fair, Connexion Point will be recruiting new applicants as well as holding onsite interviews. ...
(Date:7/6/2015)... Angeles, CA (PRWEB) , ... July 06, 2015 , ... ... for finding medical providers for personal injury victims. Throughout the company’s history the ... collectively deliver the care victims need in their recovery. And while Doctors on ...
Breaking Medicine News(10 mins):Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 2Health News:Los Angeles Cosmetic Dentist, Poneh Ghasri DDS, Now Offers Promotions on Whitening Treatments 3Health News:Office Practicum Announces new CFO 2Health News:ISI Telemanagement Solutions, Inc. Releases Service Pack 5600 for Infortel® Select 2Health News:Connexion Point, a tech enabled healthcare services company, is holding on-site job fair July 8th and 9th to fill 400 positions at its new Memphis location 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 2Health News:Doctors on Liens Adds Transportation to Its Ever-Expanding Network 3
... April 30 Retirement Living TV (RLTV) ... to bring a compelling,dialogue on the healthcare ... Virginia and Southern Delaware television markets through ... The nation,s leading,political and public leaders present ...
... April 30 Brown & Toland Medical Group,today announced ... of $12 million on total revenues of $235 million., ... million for,pay for performance and other related bonuses from ... distribute an additional $8.2,million in bonus payments to eligible ...
... study finds antidepressant cut inflammation in relapsing remitting ... may help reduce disease activity in people with the ... study suggests. , Forty patients with the disease were ... of fluoxetine (Prozac) or a placebo for 24 weeks. ...
... in heart rate variability, researchers report, , , WEDNESDAY, April ... show that the electromagnetic field produced by incubators affect ... , Whether these changes in cardiac rhythms have long-term ... premature infants who can spend several weeks or months ...
... during its Q1 2008 ... conference call on May 8 -, ... the "Company") (NASDAQ: SXCI , TSX: SXC), a leading provider,of ... (NASDAQ: NMHC ), announce that the previously,announced acquisition of NMHC ...
... to Both Reduce Exacerbations ... and Improve Lung Function, ... and Drug Administration today approved Advair Diskus(R) 250/50,(fluticasone propionate 250 ... exacerbations in patients with chronic obstructive,pulmonary disease (COPD) who have ...
Cached Medicine News:Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 2Health News:Retirement Living TV Partners with Maryland Public Television to Address the Issue of Healthcare in America Through Its Series Healthcare '08: Search for Solutions 3Health News:Brown & Toland Announces 2007 Financial Results 2Health News:Prozac Reduces Disease Activity in MS Patients 2Health News:Incubators Affect Newborns' Heart Rates 2Health News:SXC Health Solutions completes acquisition of NMHC 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 2Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 3Health News:FDA Approves Advair(R) 250/50 for Reduction of Exacerbations in Patients With COPD 4
The IntraStent DoubleStrut Biliary Stent represents a completely new direction in stent design. The combination of parallel struts and unique cell geometry provide unparalleled performance....
The Smart Check Syphilis Device is a qualitative membrane device based immunoassay for the detection of TP (Treponema Pallidum) antibodies in whole blood/serum/plasma. For professional in vitro diagn...
Bio-Quant, Inc. OneStep hCG InstaTest is an immunochromatographic assay designed for qualitative determination of human chorionic gonadotropin (hCG) in urine for early detection of pregnancy....
OneStep Midstream Urine hCG Pregnancy InstaTest is a test kit for the determination of hCG(Human Chorionic Gonadotropin) in urine specimens. This test kit is used to obtain a visual, qualitative resu...
Medicine Products: